CLDX Share Price

Open 3.31 Change Price %
High 3.36 1 Day -0.01 -0.31
Low 3.26 1 Week -0.23 -6.59
Close 3.26 1 Month -0.07 -2.10
Volume 1165379 1 Year -3.61 -52.55
52 Week High 8.75
52 Week Low 2.85
CLDX Important Levels
Resistance 2 3.35
Resistance 1 3.31
Pivot 3.29
Support 1 3.21
Support 2 3.17
NASDAQ USA Most Active Stocks
NVDA 100.49 -9.27%
JBHT 97.31 -1.05%
AREX 2.96 -1.99%
OZRK 55.54 1.02%
FNSR 34.15 0.12%
AGNC 19.64 0.72%
EA 86.65 -0.84%
FNFG 10.18 -0.20%
PRFZ 118.04 -0.80%
DELL 13.86 0.22%
More..
NASDAQ USA Top Gainers Stocks
ECTE 0.18 50.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
ZAZA 0.06 20.00%
JAKK 5.70 12.87%
LINE 0.18 12.50%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Celldex Therapeutics, Inc. (NASDAQ: CLDX)

CLDX Technical Analysis 5
As on 23rd Feb 2017 CLDX Share Price closed @ 3.26 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.96 & Strong Sell for SHORT-TERM with Stoploss of 3.57 we also expect STOCK to react on Following IMPORTANT LEVELS.
CLDX Target for February
1st Target up-side 3.73
2nd Target up-side 4.06
3rd Target up-side 4.39
1st Target down-side 2.79
2nd Target down-side 2.46
3rd Target down-side 2.13
CLDX Other Details
Segment EQ
Market Capital 363793952.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celldextherapeutics.com
CLDX Address
CLDX
Perryville III Building
53 Frontage Road
Hampton, NJ 08827
United States
Phone: 908-200-7500
Fax: 908-454-1911
Interactive Technical Analysis Chart Celldex Therapeutics, Inc. ( CLDX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Celldex Therapeutics, Inc.
CLDX Business Profile
Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.